Comparative Pharmacology
Head-to-head clinical analysis: DIDANOSINE versus EMTRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIDANOSINE versus EMTRIVA.
DIDANOSINE vs EMTRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that is converted to its active metabolite, dideoxyadenosine triphosphate (ddATP), which inhibits HIV reverse transcriptase and competes with the natural substrate dATP, leading to chain termination of viral DNA synthesis.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Weight-adjusted oral dose: 400 mg once daily (tablets) or 250 mg once daily (buffered powder) for adults ≥60 kg; 250 mg once daily (tablets) or 167 mg once daily (buffered powder) for adults <60 kg. Administer on an empty stomach (at least 30 minutes before or 2 hours after a meal).
Emtricitabine 200 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDidanosine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Atazanavir
"The serum concentration of Atazanavir can be decreased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Didanosine."
Clinical Note
moderateDidanosine + Rilpivirine
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; prolonged to 4-8 hours in renal impairment.
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose. Biliary/fecal elimination is minimal (<20%).
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The serum concentration of Rilpivirine can be increased when it is combined with Didanosine."